Literature DB >> 20711555

[Therapeutic alternatives for antihistamine-refractory urticaria].

M Maurer1, S Altrichter, E Ardelean, K Krause, M Magerl, M Metz, F Siebenhaar, K Weller, T Zuberbier.   

Abstract

Patients with chronic spontaneous urticaria, the most frequent non-acute form of urticaria, generally exhibit a clinical picture of persistent disease, a high degree of disease activity, considerable impairment of quality of life, and poor response to treatment. More than half of the patients continue to develop symptoms despite standard therapy with non-sedating antihistamines. In these cases, the antihistamine dose should be increased (up to four times the daily dose). If this approach also does not result in symptom control, the high-dose antihistamine should be combined with a leukotriene antagonist and if necessary an H2 blocker. If the patient does not respond to this combination therapy, cyclosporin A, dapsone, or omalizumab should be administered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20711555     DOI: 10.1007/s00105-010-1934-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  22 in total

1.  Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab.

Authors:  Markus Magerl; Petra Staubach; Sabine Altrichter; Elena Ardelean; Karoline Krause; Martin Metz; Karsten Weller; Marcus Maurer
Journal:  J Allergy Clin Immunol       Date:  2010-07-31       Impact factor: 10.793

2.  Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy.

Authors:  K Krause; E Ardelean; B Kessler; M Magerl; M Metz; F Siebenhaar; K Weller; M Worm; T Zuberbier; M Maurer
Journal:  Allergy       Date:  2010-11       Impact factor: 13.146

3.  Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy.

Authors:  M Metz; P Bergmann; T Zuberbier; M Maurer
Journal:  Allergy       Date:  2008-02       Impact factor: 13.146

4.  Therapeutic alternatives for chronic urticaria: additional reports on omalizumab.

Authors:  Sheldon L Spector; Ricardo A Tan
Journal:  Ann Allergy Asthma Immunol       Date:  2008-12       Impact factor: 6.347

5.  Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria.

Authors:  C E Grattan; B F O'Donnell; D M Francis; N Niimi; R J Barlow; P T Seed; A Kobza Black; M W Greaves
Journal:  Br J Dermatol       Date:  2000-08       Impact factor: 9.302

6.  EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.

Authors:  T Zuberbier; R Asero; C Bindslev-Jensen; G Walter Canonica; M K Church; A M Giménez-Arnau; C E H Grattan; A Kapp; M Maurer; H F Merk; B Rogala; S Saini; M Sánchez-Borges; P Schmid-Grendelmeier; H Schünemann; P Staubach; G A Vena; B Wedi
Journal:  Allergy       Date:  2009-10       Impact factor: 13.146

7.  How to assess disease activity in patients with chronic urticaria?

Authors:  A Młynek; A Zalewska-Janowska; P Martus; P Staubach; T Zuberbier; M Maurer
Journal:  Allergy       Date:  2008-06       Impact factor: 13.146

8.  High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study.

Authors:  Frank Siebenhaar; Franziska Degener; Torsten Zuberbier; Peter Martus; Marcus Maurer
Journal:  J Allergy Clin Immunol       Date:  2009-02-06       Impact factor: 10.793

9.  Treatment of chronic autoimmune urticaria with omalizumab.

Authors:  Allen P Kaplan; Kusumam Joseph; Robert J Maykut; Gregory P Geba; Robert K Zeldin
Journal:  J Allergy Clin Immunol       Date:  2008-09       Impact factor: 10.793

10.  Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria.

Authors:  B Engin; M Ozdemir
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-12-13       Impact factor: 6.166

View more
  1 in total

Review 1.  Dapsone in dermatology and beyond.

Authors:  Gottfried Wozel; Christian Blasum
Journal:  Arch Dermatol Res       Date:  2013-12-06       Impact factor: 3.017

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.